Ghrelin is predominantly produced by the gastric enteroendocrine cell compartment and is octanoylated by the recently discovered ghrelin o-acyltransferase (GOAT) before secretion into the bloodstream. This octanoyla...Ghrelin is predominantly produced by the gastric enteroendocrine cell compartment and is octanoylated by the recently discovered ghrelin o-acyltransferase (GOAT) before secretion into the bloodstream. This octanoylation is essential for many of the biological properties of ghrelin including appetite stimulation and anti-inflammatory properties as only the acylated form of ghrelin binds to the ghrelin receptor, the growth hormone secretagogue receptor (GHS-R). Given the gastric location of ghrelin production, it is perhaps not surprising that insult to the gastric mucosa affects circulating ghrelin levels in humans. Helicobacter pylori (H. pylon) infects more than fifty percent of the world's population and once established within the gastric mucosa, can persist for life. Infection is associated with chronic gastritis, gastric atrophy and ulceration, reduced appetite and a lower body mass index (BMI). The large majority of studies investigating levels of circulating ghrelin and ghrelin expression in the stomach in patients with H. pylori infection indicate that the bacterium has a negative impact on ghrelin production and/or secretion. Eradication of infection restores ghrelin, improves appetite and increases BMI in some studies, however, a causative relationship between H. pylori-associated serum ghrelin decline and food intake and obesity has not been established. Most studies measure total ghrelin in the circulation although the measurement of the ratio of acyl/total ghrelin gives a clearer indication that the ghrelin acylation process is altered during infection and atrophy. GOAT is essential for the production of biologically-active, acyl ghrelin and the impact of H. pylori on GOAT expression and activity will be highly informative in the future.展开更多
Objective:Depression is a global and growing health issue.Complementary and alternative medicines (CAM) use is common among people with depression.We examined the baseline use of CAM (products,not services) in central...Objective:Depression is a global and growing health issue.Complementary and alternative medicines (CAM) use is common among people with depression.We examined the baseline use of CAM (products,not services) in centrally obese adults with depression,a specific and increasingly important population who were part of a trial of Tai Chi and Qigong for depression.Methods:Self-reported use of CAM products (four major groups:vitamins,herbal medicines,mineral supplements and purified chemicals as nutritional supplements) together with demographic,lifestyle and health status characteristics were collected using validated questions within a written survey.We used descriptive statistics to understand patterns of use.Results:Two hundred and sixty patients participated in the assessment.Half of the patients stated they were using CAM,on average reporting 2.3 CAM per patient.Women were more likely than men,and older people (>60 years) more likely than younger people (<40 years) to use any CAM products.Patients reported using CAM mostly for general health and alleviating aches and pains.CAM use was not associated with health state,use of a prescription antidepressant medicine,nor (self-reported) comorbidities such as arthritis,diabetes,hypertension or alcohol or tobacco use.Conclusions:CAM products are commonly used in Australians with moderate depression,particularly in female or older patients.The range and number of CAM in this group with common comorbidity may present additional unknown risks due to potential interactions with other prescribed medications with a myriad of biological and pharmacological effects.The importance of establishing whether depressed patients are taking CAM,the particular CAM and whether the CAM interacts with each other,other drugs used for depression or the biological process of the depression itself are factors to be considered at each assessment.展开更多
基金Supported by The Swedish Research Council (Vetenskapsrdet: K2008-58X-20693-01-4)Novo Nordisk Foundation (SL), National Health and Medical Research Council of Australia (Project No. 488811) and a Queensland Government Smart Futures Fellowship (PLJ)
文摘Ghrelin is predominantly produced by the gastric enteroendocrine cell compartment and is octanoylated by the recently discovered ghrelin o-acyltransferase (GOAT) before secretion into the bloodstream. This octanoylation is essential for many of the biological properties of ghrelin including appetite stimulation and anti-inflammatory properties as only the acylated form of ghrelin binds to the ghrelin receptor, the growth hormone secretagogue receptor (GHS-R). Given the gastric location of ghrelin production, it is perhaps not surprising that insult to the gastric mucosa affects circulating ghrelin levels in humans. Helicobacter pylori (H. pylon) infects more than fifty percent of the world's population and once established within the gastric mucosa, can persist for life. Infection is associated with chronic gastritis, gastric atrophy and ulceration, reduced appetite and a lower body mass index (BMI). The large majority of studies investigating levels of circulating ghrelin and ghrelin expression in the stomach in patients with H. pylori infection indicate that the bacterium has a negative impact on ghrelin production and/or secretion. Eradication of infection restores ghrelin, improves appetite and increases BMI in some studies, however, a causative relationship between H. pylori-associated serum ghrelin decline and food intake and obesity has not been established. Most studies measure total ghrelin in the circulation although the measurement of the ratio of acyl/total ghrelin gives a clearer indication that the ghrelin acylation process is altered during infection and atrophy. GOAT is essential for the production of biologically-active, acyl ghrelin and the impact of H. pylori on GOAT expression and activity will be highly informative in the future.
文摘Objective:Depression is a global and growing health issue.Complementary and alternative medicines (CAM) use is common among people with depression.We examined the baseline use of CAM (products,not services) in centrally obese adults with depression,a specific and increasingly important population who were part of a trial of Tai Chi and Qigong for depression.Methods:Self-reported use of CAM products (four major groups:vitamins,herbal medicines,mineral supplements and purified chemicals as nutritional supplements) together with demographic,lifestyle and health status characteristics were collected using validated questions within a written survey.We used descriptive statistics to understand patterns of use.Results:Two hundred and sixty patients participated in the assessment.Half of the patients stated they were using CAM,on average reporting 2.3 CAM per patient.Women were more likely than men,and older people (>60 years) more likely than younger people (<40 years) to use any CAM products.Patients reported using CAM mostly for general health and alleviating aches and pains.CAM use was not associated with health state,use of a prescription antidepressant medicine,nor (self-reported) comorbidities such as arthritis,diabetes,hypertension or alcohol or tobacco use.Conclusions:CAM products are commonly used in Australians with moderate depression,particularly in female or older patients.The range and number of CAM in this group with common comorbidity may present additional unknown risks due to potential interactions with other prescribed medications with a myriad of biological and pharmacological effects.The importance of establishing whether depressed patients are taking CAM,the particular CAM and whether the CAM interacts with each other,other drugs used for depression or the biological process of the depression itself are factors to be considered at each assessment.